活体生物发光成像用于葡萄膜炎动物模型炎症的纵向监测
研究在C57BL/6白化小鼠中建立三种实验性葡萄膜炎模型(PMU、EIU、EAU),用腹腔注射鲁米诺钠盐作为发光底物,通过IVIS Spectrum采集生物发光图像。PMU和EIU模型炎症高峰期生物发光较基线显著升高(P=0.01和P=0.04),EAU模型升高未达统计学显著。作者认为活体生物发光可作为葡萄膜炎动物模型眼内炎症的无创定量监测手段。
要点
- PMU眼炎症高峰期生物发光为1.46×10^5 p/s,显著高于基线1.47×10^4 p/s(P=0.01)。
- EIU眼炎症高峰期生物发光为3.18×10^4 p/s,显著高于基线1.09×10^4 p/s(P=0.04),48小时回落至接近基线。
- EAU模型炎症高峰期生物发光升高未达统计学显著。
核心结论
- 活体生物发光或可作为葡萄膜炎动物模型眼内炎症的无创定量测量方法。
- PMU和EIU均为伴有明显前节炎症的急性模型,其生物发光变化与炎症高峰期相对应。
- EAU为较隐匿的后节葡萄膜炎,产生的生物发光信号较微弱。
- IVIS生物发光是一种非致死、可定量的检测方法,可用于监测葡萄膜炎动物模型的炎症。
研究设计与样本
- 在C57BL/6白化小鼠中诱导三种实验性葡萄膜炎模型:初免分枝杆菌葡萄膜炎(PMU)、内毒素诱导葡萄膜炎(EIU)和实验性自身免疫性葡萄膜炎(EAU)。
- 腹腔注射氧化时发光的鲁米诺钠盐作为生物发光底物,用PerkinElmer IVIS Spectrum采集图像,并用Living Image软件分析总生物发光。
- 每个模型比较第0天与炎症高峰期当天的生物发光,并在EIU和EAU中进行纵向生物发光成像。
主要发现
- 在有鲁米诺存在时,三种小鼠葡萄膜炎模型的眼内炎症均可产生可检测的生物发光。
- PMU眼炎症高峰期生物发光为1.46×10^5 photons/second(p/s),显著高于基线1.47×10^4 p/s(P=0.01)。
- EIU眼炎症高峰期生物发光为3.18×10^4 p/s,显著高于基线1.09×10^4 p/s(P=0.04),并在48小时回落至接近基线水平。
- EAU中炎症高峰期生物发光升高未达统计学显著。
关键数值与推荐
- PMU眼:炎症高峰期1.46×10^5 p/s vs 基线1.47×10^4 p/s,P=0.01。
- EIU眼:炎症高峰期3.18×10^4 p/s vs 基线1.09×10^4 p/s,P=0.04。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We develop a quantitative bioluminescence assay for in vivo longitudinal monitoring of inflammation in animal models of uveitis. METHODS: Three models of experimental uveitis were induced in C57BL/6 albino mice: primed mycobacterial uveitis (PMU), endotoxin-induced uveitis (EIU), and experimental autoimmune uveitis (EAU). Intraperitoneal injection of luminol sodium salt, which emits light when oxidized, provided the bioluminescence substrate. Bioluminescence images were captured by a PerkinElmer In Vivo Imaging System (IVIS) Spectrum and total bioluminescence was analyzed using Living Image software. Bioluminescence on day zero was compared to bioluminescence on the day of peak inflammation for each model. Longitudinal bioluminescence imaging was performed in EIU and EAU. RESULTS: In the presence of luminol, intraocular inflammation generates detectable bioluminescence in three mouse models of uveitis. Peak bioluminescence in inflamed PMU eyes (1.46 × 105 photons/second [p/s]) was significantly increased over baseline (1.47 × 104 p/s, P = 0.01). Peak bioluminescence in inflamed EIU eyes (3.18 × 104 p/s) also was significantly increased over baseline (1.09 × 104 p/s, P = 0.04), and returned to near baseline levels by 48 hours. In EAU, there was a nonsignificant increase in bioluminescence at peak inflammation. CONCLUSIONS: In vivo bioluminescence may be used as a noninvasive, quantitative measure of intraocular inflammation in animal models of uveitis. Primed mycobacterial uveitis and EIU are both acute models with robust anterior inflammation and demonstrated significant changes in bioluminescence corresponding with peak inflammation. Experimental autoimmune uveitis is a more indolent posterior uveitis and generated a more modest bioluminescent signal. In vivo imaging system bioluminescence is a nonlethal, quantifiable assay that can be used for monitoring inflammation in animal models of uveitis.
引用
- Gutowski MB, Wilson L, Van Gelder RN, et al. In Vivo Bioluminescence Imaging for Longitudinal Monitoring of Inflammation in Animal Models of Uveitis. Invest Ophthalmol Vis Sci. 2017. PMID: 28278321. doi:10.1167/iovs.16-20824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。